What is a stock summary page? Click here for an overview.
Business Description
Intellia Therapeutics Inc
NAICS : 325413
SIC : 2835
ISIN : US45826J1051
Description
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.86 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | -0.4 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.84 | |||||
| Beneish M-Score | -2.88 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.9 | |||||
| 3-Year EBITDA Growth Rate | -12.9 | |||||
| 3-Year EPS without NRI Growth Rate | -9.2 | |||||
| 3-Year FCF Growth Rate | -2.3 | |||||
| 3-Year Book Growth Rate | -15.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 6.39 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 78.06 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.77 | |||||
| 9-Day RSI | 36.21 | |||||
| 14-Day RSI | 38.64 | |||||
| 3-1 Month Momentum % | -15.71 | |||||
| 6-1 Month Momentum % | -51.95 | |||||
| 12-1 Month Momentum % | -63.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.77 | |||||
| Quick Ratio | 5.77 | |||||
| Cash Ratio | 5.43 | |||||
| Days Sales Outstanding | 129.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.1 | |||||
| Shareholder Yield % | -22.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -923.1 | |||||
| Net Margin % | -896.77 | |||||
| FCF Margin % | -612.78 | |||||
| ROE % | -53.05 | |||||
| ROA % | -42.43 | |||||
| ROIC % | -110.03 | |||||
| 3-Year ROIIC % | 11803.85 | |||||
| ROC (Joel Greenblatt) % | -327.49 | |||||
| ROCE % | -47.86 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 13.65 | |||||
| PB Ratio | 0.94 | |||||
| Price-to-Tangible-Book | 0.94 | |||||
| EV-to-EBIT | -0.9 | |||||
| EV-to-Forward-EBIT | -0.84 | |||||
| EV-to-EBITDA | -0.91 | |||||
| EV-to-Forward-EBITDA | -0.9 | |||||
| EV-to-Revenue | 8.26 | |||||
| EV-to-Forward-Revenue | 11 | |||||
| EV-to-FCF | -1.35 | |||||
| Price-to-GF-Value | 0.25 | |||||
| Price-to-Net-Current-Asset-Value | 2.57 | |||||
| Price-to-Net-Cash | 2.91 | |||||
| Earnings Yield (Greenblatt) % | -111.11 | |||||
| FCF Yield % | -42.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NTLA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Intellia Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 57.877 | ||
| EPS (TTM) ($) | -5.25 | ||
| Beta | 1.8 | ||
| 3-Year Sharpe Ratio | -1.06 | ||
| 3-Year Sortino Ratio | -1.24 | ||
| Volatility % | 50.33 | ||
| 14-Day RSI | 38.64 | ||
| 14-Day ATR ($) | 0.736767 | ||
| 20-Day SMA ($) | 9.2755 | ||
| 12-1 Month Momentum % | -63.32 | ||
| 52-Week Range ($) | 8.03 - 28.18 | ||
| Shares Outstanding (Mil) | 103.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intellia Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Intellia Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Intellia Therapeutics Inc Frequently Asked Questions
What is Intellia Therapeutics Inc(NTLA)'s stock price today?
The current price of NTLA is $8.07. The 52 week high of NTLA is $28.18 and 52 week low is $8.03.
When is next earnings date of Intellia Therapeutics Inc(NTLA)?
The next earnings date of Intellia Therapeutics Inc(NTLA) is 2025-05-09 Est..
Does Intellia Therapeutics Inc(NTLA) pay dividends? If so, how much?
Intellia Therapeutics Inc(NTLA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers